Reference : Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitar...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/56681
Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications.
English
Jaffrain-Rea, M. L. [> > > >]
Angelini, M. [ > > ]
Gargano, D. [ > > ]
Tichomirowa, M. A. [ > > ]
Daly, Adrian [Université de Liège - ULg > Département des sciences cliniques > Endocrinologie >]
Vanbellinghen, Jean-François [Université de Liège - ULg > > Centre de diagnostic moleculaire >]
D'Innocenzo, E. [ > > ]
Barlier, A. [ > > ]
Giangaspero, F. [ > > ]
Esposito, Vincenzina [Université de Liège - ULg > > Centre d'études et de rech. sur les macromolécules (CERM) >]
Ventura, L. [ > > ]
Arcella, A. [ > > ]
Theodoropoulou, M. [ > > ]
Naves, L. A. [ > > ]
Fajardo, C. [ > > ]
Zacharieva, S. [ > > ]
Rohmer, V. [ > > ]
Brue, T. [ > > ]
Gulino, A. [ > > ]
Cantore, G. [ > > ]
Alesse, E. [ > > ]
Beckers, Albert mailto [Université de Liège - ULg > Département des sciences cliniques > Endocrinologie >]
Sep-2009
Endocrine-Related Cancer
Society for Endocrinology
16
3
1029-1043
Yes (verified by ORBi)
International
1351-0088
1479-6821
Bristol
United Kingdom
[en] Adenoma/genetics/metabolism/pathology ; Adolescent ; Adult ; Child ; Gene Expression Regulation, Neoplastic ; Humans ; Intracellular Signaling Peptides and Proteins/genetics/metabolism ; Middle Aged ; Mutation ; Neoplasm Invasiveness ; Phenotype ; Pituitary Gland/metabolism ; Pituitary Neoplasms/genetics/metabolism/pathology ; Prolactinoma/genetics/metabolism/pathology ; Receptors, Aryl Hydrocarbon/genetics/metabolism ; Young Adult
[en] Germline mutations of the aryl hydrocarbon receptor (AHR)-interacting protein (AIP) gene confer a predisposition to pituitary adenomas (PA), usually in the setting of familial isolated PA. To provide further insights into the possible role of AIP in pituitary tumour pathogenesis, the expression of AIP and AHR was determined by real-time RT-PCR and/or immunohistochemistry (IHC) in a large series of PA (n=103), including 17 with AIP mutations (AIP(mut)). Variable levels of AIP and AHR transcripts were detected in all PA, with a low AHR expression (P<0.0001 versus AIP). Cytoplasmic AIP and AHR were detected by IHC in 84.0 and 38.6% of PA respectively, and significantly correlated with each other (P=0.006). Nuclear AHR was detected in a minority of PA (19.7%). The highest AIP expression was observed in somatotrophinomas and non-secreting (NS) PA, and multivariate analysis in somatotrophinomas showed a significantly lower AIP immunostaining in invasive versus non-invasive cases (P=0.019). AIP expression was commonly low in other secreting PA. AIP immunostaining was abolished in a minority of AIP(mut) PA, with a frequent loss of cytoplasmic AHR and no evidence of nuclear AHR. In contrast, AIP overexpression in a subset of NS PA could be accompanied by nuclear AHR immunopositivity. We conclude that down-regulation of AIP and AHR may be involved in the aggressiveness of somatotrophinomas. Overall, IHC is a poorly sensitive tool for the screening of AIP mutations. Data obtained on AHR expression suggest that AHR signalling may be differentially affected according to PA phenotype.
Researchers ; Professionals
http://hdl.handle.net/2268/56681
10.1677/ERC-09-0094

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Jaffrain-Rea al AHRAIP ERC 2009.pdfPublisher postprint584.91 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.